We developed a new assay of Bcl-x L inhibitors based on fluorescence resonance energy transfer that occurs between an AEDANS-labeled Bak-BH3 peptide and three tryptophans in the BH1 and BH2 domains of Bclx L . The method can tolerate up to 5% DMSO, and it was validated with several Bcl-x L inhibitors. It can be adapted to screen for compounds targeting other Bcl-2 family proteins.
The Bcl-2 family is composed of a set of proteins whose amino acid sequences contain up to four homologous regions termed BH1-BH4 domains. As the key regulator of apoptosis, Bcl-2 family proteins control cell death by forming homo-and heterodimers among the anti-apoptotic and pro-apoptotic members of the family. Anti-apoptotic proteins, such as Bcl-2 and Bcl-x L , are overexpressed in many cancer cells and are related to tumor initiation, development, and resistance to chemotherapy. 1) Peptides derived from the BH3 domain of pro-apoptotic proteins can bind with antiapoptotic proteins and induce apoptosis of cancer cells with a high expression level of Bcl-2 or Bcl-x L . 2, 3) The complex structures of several BH3 peptides with Bcl-x L have been solved by crystallographic and NMR techniques, showing that the peptides bind to a hydrophobic cleft constituted by BH3, BH1, and BH2 domain residues of Bcl-x L . [4] [5] [6] [7] Thus compounds mimicking BH3 peptides binding to the hydrophobic pocket can induce the apoptosis of cancer cells, and hence have potential application in cancer therapy. To date, two assay methods, based on fluorescence polarization (FP) and NMR techniques, have been developed to determine the binding affinity of Bcl-x L inhibitors. 8, 9) Though both methods are sensitive for interaction study between the compounds and Bcl-x L , they require accessibility by particular instruments, such as a fluorescence polarimeter or an NMR spectrometer. The intrinsic properties of these methods can limit their application under certain circumstances. For example, NMR binding assay requires the preparation of relatively high concentrations of Bcl-x L protein. Many testing compounds are insoluble in water and must first be solubilized in dimethyl sulfoxide (DMSO). When the compounds are titrated into NMR tubes, DMSO can cause precipitation of the protein. As to FP binding assay, efforts has to be made to optimize the substrate peptide sequence, the fluorescence dye, and the labeling position so that sufficient sensitivity of the method can be achieved. To overcome these limitations, we developed a new assay based on the fluorescence resonance energy transfer (FRET) technique to determine the binding affinity of Bcl-x L inhibitors.
As revealed by the complex structure of Bcl-x L with BH3 domain peptide from Bak, three adjacent tryptophan residues of Bcl-x L (viz., Trp137, Trp181, and Trp188) form a hydrophobic cluster that is close to the binding site for the BH3 domain peptide (Fig. 1A) . The fluorescence emission of tryptophan is centered at about 340 nm, which coincides to the fluorescence excitation wavelength of AEDANS (5-((((2-iodoacetyl)amino)-ethyl)amino)naphthalene-1-sulfonic acid). We took advantage of this structural property of Bcl-x L to attach the fluorescence dye AEDANS to the proper residue of the Bak-BH3 peptide so that fluorescence resonance energy transfer would occur between the tryptophan hydrophobic cluster and the fluorescence dye. According to the complex structure of Bcl-x L with Bak-BH3 peptide (GQVGRQLAIIGDDINR), the distances between the C atoms of the asparagine of Bak-BH3 peptide and the three tryptophans of Bcl-x L are 8 Å , 18 Å , and 16 Å respectively, in the range of the Förster critical distance y To whom correspondence should be addressed. Fax: +86-21-50806065; E-mail: dxl@mail.shcnc.ac.cn Biosci. Biotechnol. Biochem., 72 (7), [1936] [1937] [1938] [1939] 2008 Note for Trp-AEDANS (22 Å ). [10] [11] [12] Moreover, the asparagine of Bak-BH3 peptide is not involved in the interaction with Bcl-x L . 5) Hence we replaced the asparagine with cysteine and labeled the fluorescence dye AEDANS at this residue. The thiol reaction of the cysteine with AEDANS was performed at 4 C in PBS buffer, pH 7.4, overnight. The labeled peptide was purified by conventional HPLC (C18 column, 250 Â 10 mm, gradient from 5% to 40% acetonitrile in H 2 O with 0.1% TFA over 30 min at a speed of 4 ml/min). When AEDANS-labeled Stock solutions of 1 mM AEDANS-labeled Bak-BH3 peptide and unlabeled Bak-BH3 peptide were prepared by dissolving particular weights of lyophilized peptides powder in PBS buffer (pH 7.4). 50 mM HA14-1 stock solution and 10 mM BH3I-1 stock solution were prepared by dissolving particular weights of compounds in DMSO. The concentrations of Bcl-x L and BSA were determined by the absorbance at 280 nm in 6 M guanidine HCl using extinction coefficients of 41,940 M À1 Ácm À1 and 43,824 M À1 Ácm À1 respectively. All fluorescence measurements were performed on an F-2500 fluorescence spectrophotometer (Hitachi, Tokyo) at room temperature. The inner section of the fluorescence cuvette was 5 mm Â 5 mm square, and the volume of reaction mixture was 200 ml. A, Bak-BH3 peptide is situated in the hydrophobic groove constituted by BH3, BH1, and BH2 domain residues of Bcl-x L according to the complex structure of Bcl-x L /Bak peptide (PBD ID 1BXL). The tryptophan residues of Bcl-x L and the cysteine of Bak-BH3 peptide are rendered in stick. The distances between C atoms of the cysteine of Bak-BH3 peptide and three tryptophans of Bcl-x L are 8 Å , 18 Å , and 16 Å respectively, in the range of the Förster critical distance for Trp-AEDANS (22 Å ). B, The binding of Bcl-x L with AEDANS-labeled Bak-BH3 peptide causes the occurrence of fluorescence resonance energy transfer between the three tryptophans of Bcl-x L and AEDANS on the labeled Bak-BH3 peptide. The fluorescence spectra of Bcl-x L were measured at 300-550 nm with an excitation light of 280 nm. When 10 mM AEDANS-labeled Bak-BH3 peptide was added to 3.5 mM Bcl-x L (PBS, pH 7.4), the fluorescence emission at 340 nm from the tryptophans of Bcl-x L was transferred to AEDANS. As a consequence, the fluorescence intensity at 340 nm decreased and a new fluorescence emission from AEDANS appeared at 490 nm. In contrast, when 10 mM AEDANS-labeled Bak-BH3 peptide was added to 3.5 mM BSA (PBS, pH 7.4), no FRET was observed. C, Determination of the binding affinity K d of Bcl-x L with AEDANSlabeled Bak-BH3 peptide. Bcl-x L (3.5 mM) was incubated with different concentrations of AEDANS-labeled Bak-BH3 peptide. After 1 h of incubation at room temperature in PBS buffer (pH 7.4), the fluorescence emission at 490 nm was recorded with an excitation light of 280 nm. The fluorescence from AEDANS-labeled Bak-BH3 peptide was subtracted. The solid line is the saturation curve fitted to the experimental data points by nonlinear least-squares regression analysis to calculate the dissociation constant K d according to equations 1 and 2. D, Competitive binding assay of the unlabeled Bak-BH3 peptide and Bcl-x L inhibitors. Bcl-x L was pre-incubated with AEDANS-labeled Bak-BH3 peptide for 1 h at room temperature (PBS, pH 7.4). Then various concentrations of Bak-BH3 peptide (0.07-40 mM), HA14-1 (2-500 mM), or BH3I-1 (0.78-100 mM) were added to compete with AEDANS-labeled Bak-BH3 peptide. After 1 h of incubation at room temperature, the fluorescence at 490 nm was recorded with an excitation wavelength of 280 nm. E, F, Effects of DMSO and ionic strength on the FRET signal at 490 nm. Bcl-x L (0.5 mM) and 2.5 mM AEDANS-labeled Bak-BH3 peptide were incubated with various concentrations of DMSO (PBS, pH 7.4) or NaCl (20 mM Tris, pH 7.4) for 1 h at room temperature. The fluorescence emission was recorded at 490 nm with an excitation wavelength of 280 nm.
Bak-BH3 peptide was added to Bcl-x L , the fluorescence energy at 340 nm from the tryptophans of Bcl-x L was transferred to AEDANS. Consequently, the fluorescence intensity at 340 nm decreased and a new fluorescence emission from AEDANS appeared at 490 nm (Fig. 1B) 
The fraction of bound Bcl-x L , [RL]/[R] 0 , was calculated by equation (2), where is the fluorescence intensity at 490 nm of the Bcl-x L sample mixed with particular amounts of AEDANS-labeled Bak-BH3 peptide, min is the fluorescence at 490 nm of Bcl-x L without AEDANS-labeled Bak-BH3 peptide, and max is the fluorescence at 490 nm of Bcl-x L with an excessive amount of AEDANS-labeled Bak-BH3 peptide:
According to equation 1, the dissociation constant K d of AEDANS-labeled Bak-BH3 peptide with Bcl-x L was determined to be 0.3 mM (Fig. 1C) , which is consistent with previously reported values of 0.38 mM and 0.34 mM. 8, 13) The similar dissociation constants indicate that the replacement of asparagine with cysteine and the labeling of AEDANS at this residue did not affect the interaction of Bak-BH3 peptide with Bcl-x L .
To determine the binding affinity of potential Bcl-x L inhibitors, we developed a competitive binding assay based on the FRET method. Bcl-x L (0.5 mM, in PBS, pH 7.4) was pre-incubated with 2.5 mM AEDANSlabeled Bak-BH3 peptide for 1 h. Then various concentrations of the inhibitors were added to compete with the AEDANS-labeled Bak-BH3 peptide. After 1 h of incubation at room temperature, the fluorescence at 490 nm (excited by 280 nm) was recorded. Concentrations of Bcl-x L and AEDANS-labeled Bak-BH3 peptide were chosen based on the consideration that 90% Bcl-x L was bound by AEDANS-labeled BH3 peptide according to equation 1, which makes the competitive binding assay more sensitive (Fig. 1C) . To validate the assay method, we measured the IC 50 of several reported Bcl-x L inhibitors (Fig. 1D) . The IC 50 values for unlabeled Bak-BH3 peptide, BH3I-1, and HA14-1 to compete with the AEDANS-labeled Bak-BH3 peptide were 1.4 mM, 5.6 mM, and 240 mM respectively. Since the IC 50 value depends on the concentrations of the acceptor and the substrate ligand used in the competitive binding assay, there is some variance between our results and previous reported data. However, the order of the binding affinity of the Bcl-x L inhibitors characterized by our measured IC 50 values, Bak-BH3 > BH3I-1 > HA14-1, is in agreement with published results obtained by the fluorescence polarization method. 8, 13) We examined the effect of DMSO and ionic strength on FRET fluorescence at 490 nm. DMSO is a common solvent used to dissolve chemical compounds. According to our experiments, the FRET signal did not change significantly at concentrations of DMSO below 5% v/v (Fig. 1E) . When the concentration of DMSO reached 10% v/v, the fluorescence intensity increased by about 17%. The FRET signal remained stable in the presence of moderate concentrations of NaCl ( 500 mM), while higher ionic strength can elevate the FRET signal (Fig. 1F) . Therefore, the FRET-based assay was reasonably stable in the presence of DMSO up to 5% and in commonly used buffers such as PBS.
As shown by the sequence alignment as well as the structures of Bcl-2 (PDB ID 1G5M), Bcl-x L (PDB ID 1R2D), Bcl-w (PDB ID 1MK3), Bak (PDB ID 2JCN), Bax (PDB ID 1F16), and Bid (PDB ID 1DDB), three adjacent tryptophans of Bcl-x L forming the hydrophobic cluster are conserved among many Bcl-2 family proteins. Hence AEDANS-labeled peptides that bind into the hydrophobic clefts of the proteins probably show a FRET phenomenon with these conserved tryptophan residues. In light of this, the FRET-based assay that we devised here can be adapted to other Bcl-2 family proteins. For example, the NMR structure of Bax revealed that its C-terminal region occupies its own hydrophobic cleft constituted by BH2, BH1, and BH3 domain residues. A peptide derived from the C-terminal transmembrane domain of Bax can be synthesized and labeled with AEDANS. Accordingly, the FRET-based assay method as described here can be applied to screen for compounds that bind to Bax protein.
In summary, we developed a new assay based on fluorescence resonance energy transfer to determine the binding affinity of Bcl-x L inhibitors. The assay was stable in the presence of up to 5% v/v DMSO, and was validated with several Bcl-x L inhibitors, showing that the assay result is consistent with published data obtained by the FP method. Compared with the FP and NMR methods, the FRET-based assay has several advantages. First, it has fewer requirements for the substrate peptide as long as the peptide has sufficient binding affinity with Bcl-x L protein. Secondly, the amount of the protein sample used in the assay is less than that in the NMR binding assay. Thirdly, it is not necessary to employ a fluorescence polarimeter or an expensive NMR spectrometer. As many Bcl-2 family proteins share a similar folding pattern with the three conserved tryptophan residues at the apex of the BH1 and BH2 domains, the FRET-based assay can be adapted to screen for compounds targeting other Bcl-2 family proteins as well.
